Genentech wins Chiron patent case
Executive Summary
A Chiron patent claiming monoclonal antibodies that bind selectively to the HER-2 antigen is invalid, a federal appeals court ruled March 30. Chiron sued Genentech in 2000, claiming the firm's oncologic Herceptin (trastuzumab) infringed the Chiron patent. The Federal Circuit 1ruling affirms a Sacramento, Calif. court's judgment in favor of Genentech (2"The Pink Sheet" Sept. 16, 2002, In Brief)...